The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Pacific Biosciences of California Inc (NASDAQ: PACB) was $1.84 for the day, down -2.13% from the previous closing price of $1.88. In other words, the price has decreased by -$2.13 from its previous closing price. On the day, 9.02 million shares were traded. PACB stock price reached its highest trading level at $1.92 during the session, while it also had its lowest trading level at $1.82.
Ratios:
Our analysis of PACB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.40 and its Current Ratio is at 6.24. In the meantime, Its Debt-to-Equity ratio is 19.40 whereas as Long-Term Debt/Eq ratio is at 19.38.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 ’25 when Van Oene Mark sold 26,836 shares for $1.31 per share. The transaction valued at 35,182 led to the insider holds 1,920,035 shares of the business.
MARK VAN OENE bought 26,836 shares of PACB for $35,174 on Aug 18 ’25. On May 19 ’25, another insider, Farmer Michele, who serves as the insider of the company, sold 5,195 shares for $1.00 each. As a result, the insider received 5,200 and left with 269,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 555509696 and an Enterprise Value of 959935680. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.59 while its Price-to-Book (P/B) ratio in mrq is 15.39. Its current Enterprise Value per Revenue stands at 6.21 whereas that against EBITDA is -4.984.
Stock Price History:
The Beta on a monthly basis for PACB is 2.21, which has changed by -0.04663211 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -8.11%, while the 200-Day Moving Average is calculated to be 26.85%.
Shares Statistics:
PACB traded an average of 8.78M shares per day over the past three months and 5991590 shares per day over the past ten days. A total of 301.85M shares are outstanding, with a floating share count of 270.83M. Insiders hold about 10.29% of the company’s shares, while institutions hold 52.58% stake in the company. Shares short for PACB as of 1764288000 were 34042917 with a Short Ratio of 3.88, compared to 1761868800 on 32511384. Therefore, it implies a Short% of Shares Outstanding of 34042917 and a Short% of Float of 12.82.
Earnings Estimates
The firm’s stock currently is rated by 8.0 analysts. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.53 and -$0.56 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.5, with 7.0 analysts recommending between -$0.42 and -$0.54.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $43M to a low estimate of $40.4M. As of. The current estimate, Pacific Biosciences of California Inc’s year-ago sales were $39.22MFor the next quarter, 8 analysts are estimating revenue of $41.31M. There is a high estimate of $44M for the next quarter, whereas the lowest estimate is $38.7M.
A total of 8 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $158.17M, while the lowest revenue estimate was $155.8M, resulting in an average revenue estimate of $157.22M. In the same quarter a year ago, actual revenue was $154.01MBased on 8 analysts’ estimates, the company’s revenue will be $177.14M in the next fiscal year. The high estimate is $184.6M and the low estimate is $165.2M.
